

**Company registration number: 623175**

**McVann Pharmacy(Westport) Limited**  
**Unaudited abridged financial statements**  
**for the financial year ended 30 April 2025**

# McVann Pharmacy(Westport) Limited

## Contents

	<b>Page</b>
Director's responsibilities statement	<b>1</b>
Balance sheet	<b>2 - 3</b>
Notes to the abridged financial statements	<b>4 - 8</b>

## **McVann Pharmacy(Westport) Limited**

### **Director's responsibilities statement**

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Director's Responsibilities Statement accompanying those financial statements.

The director is responsible for preparing the director's report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under the law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable him to ensure that the financial statements and director's report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**McVann Pharmacy(Westport) Limited**

**Balance sheet  
As at 30 April 2025**

	Note	2025 €	€	2024 €	€
<b>Fixed assets</b>					
Tangible assets	5	79,641		98,830	
			79,641		98,830
<b>Current assets</b>					
Stocks	6	139,260		138,406	
Debtors	7	49,477		37,638	
Cash at bank and in hand		166,661		156,344	
		<u>355,398</u>		<u>332,388</u>	
<b>Creditors: amounts falling due within one year</b>					
	8	<u>(135,704)</u>		<u>(138,694)</u>	
<b>Net current assets</b>					
			<u>219,694</u>		<u>193,694</u>
<b>Total assets less current liabilities</b>					
			299,335		292,524
<b>Creditors: amounts falling due after more than one year</b>					
	9		(34,213)		(26,049)
<b>Net assets</b>					
			<u>265,122</u>		<u>266,475</u>
<b>Capital and reserves</b>					
Called up share capital presented as equity			100		100
Profit and loss account			<u>265,022</u>		<u>266,375</u>
<b>Shareholder funds</b>					
			<u>265,122</u>		<u>266,475</u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland'.

**The notes on pages 4 to 8 form part of these abridged financial statements.**

**McVann Pharmacy(Westport) Limited**

**Balance sheet (continued)  
As at 30 April 2025**

I, as director of McVann Pharmacy(Westport) Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholder of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the director of the company on 23 January 2026 and signed by:

MR MICHEAL MCVANN  
Director

**The notes on pages 4 to 8 form part of these abridged financial statements.**

## McVann Pharmacy(Westport) Limited

### Notes to the abridged financial statements Financial year ended 30 April 2025

#### 1. Accounting policies and measurement bases

##### **Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

##### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

##### **Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

##### **Operating leases**

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

## McVann Pharmacy(Westport) Limited

### Notes to the abridged financial statements (continued) Financial year ended 30 April 2025

#### **Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

#### **Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

#### **Impairment**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

#### **Stocks**

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

## McVann Pharmacy(Westport) Limited

### Notes to the abridged financial statements (continued) Financial year ended 30 April 2025

#### Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

#### Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

## 2. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 10 (2024: 10).

The aggregate payroll costs incurred during the financial year were:

	<b>2025</b>	2024
	€	€
Wages and salaries	291,425	237,833
Other retirement benefit costs	7,440	6,194
	<u>298,865</u>	<u>244,027</u>

**McVann Pharmacy(Westport) Limited**

**Notes to the abridged financial statements (continued)  
Financial year ended 30 April 2025**

**3. Directors remuneration**

The director's aggregate remuneration was as follows:

	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
Emoluments in respect of qualifying services	82,000	69,999
Pension contributions to defined contribution plans in respect of qualifying services	7,440	5,194
	<b>89,440</b>	<b>75,193</b>
	<b>89,440</b>	<b>75,193</b>

**4. Appropriations of profit and loss account**

	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
At the start of the financial year	266,375	226,418
(Loss)/profit for the financial year	(1,353)	39,957
<b>At the end of the financial year</b>	<b>265,022</b>	<b>266,375</b>
	<b>265,022</b>	<b>266,375</b>

**5. Tangible assets**

	Fixtures, fittings and equipment	Motor vehicles	<b>Total</b>
	<b>€</b>	<b>€</b>	<b>€</b>
<b>Cost</b>			
At 1 May 2024	264,702	47,450	312,152
Additions	3,077	46,701	49,778
Disposals	-	(47,450)	(47,450)
<b>At 30 April 2025</b>	<b>267,779</b>	<b>46,701</b>	<b>314,480</b>
	<b>267,779</b>	<b>46,701</b>	<b>314,480</b>
<b>Depreciation</b>			
At 1 May 2024	195,528	17,794	213,322
Charge for the financial year	33,472	5,838	39,310
Disposals	-	(17,793)	(17,793)
<b>At 30 April 2025</b>	<b>229,000</b>	<b>5,839</b>	<b>234,839</b>
	<b>229,000</b>	<b>5,839</b>	<b>234,839</b>
<b>Carrying amount</b>			
<b>At 30 April 2025</b>	<b>38,779</b>	<b>40,862</b>	<b>79,641</b>
	<b>38,779</b>	<b>40,862</b>	<b>79,641</b>
At 30 April 2024	69,174	29,656	98,830
	69,174	29,656	98,830

**McVann Pharmacy(Westport) Limited**

**Notes to the abridged financial statements (continued)  
Financial year ended 30 April 2025**

<b>6. Stocks</b>		<b>2025</b>	2024
		€	€
Finished goods and goods for resale		139,260	138,406
		<u>139,260</u>	<u>138,406</u>
<b>7. Debtors</b>		<b>2025</b>	2024
		€	€
Trade debtors		863	115
Other debtors		48,614	37,523
		<u>49,477</u>	<u>37,638</u>
<b>8. Creditors: amounts falling due within one year</b>		<b>2025</b>	2024
		€	€
Trade creditors		80,313	77,534
Other creditors including tax and social insurance		53,391	59,160
Accruals		2,000	2,000
		<u>135,704</u>	<u>138,694</u>
<b>9. Creditors: amounts falling due after more than one year</b>		<b>2025</b>	2024
		€	€
Amounts owed to credit institutions		-	2,000
Other creditors including tax and social insurance		34,213	40,641
		<u>34,213</u>	<u>42,641</u>
<b>10. Controlling party</b>			
	The Director is the ultimate controlling party for the company as he controls 100% of the issued share capital.		
<b>11. Approval of financial statements</b>			
	The board of directors approved these abridged financial statements for issue on 23 January 2026.		